1 sitive subjects with and without circulating
cryptococcal polysaccharide.
2 f the interaction of a host protein with the
cryptococcal polysaccharide.
3 mans; and (iv) reduced antibody responses to
cryptococcal polysaccharide.
4 s on leukocytes in subjects with circulating
cryptococcal polysaccharide and increased serum levels o
5 that CD18 is a possible molecular target of
cryptococcal polysaccharides and that binding of the pol
6 w us to explore the fine specificity of anti-
cryptococcal polysaccharide antibodies.
7 scopy with (15)N-labeled peptide mimetics of
cryptococcal polysaccharide antigen (Ag).
8 es, interactions with anti-GXM mAbs, and the
cryptococcal polysaccharide architecture.
9 Cryptococcal polysaccharides are known to either remain
10 The
cryptococcal polysaccharide capsule is a leading candida
11 In contrast,
cryptococcal polysaccharide did not induce a chemokine r
12 In the same experiments, the
cryptococcal polysaccharides did not affect the binding
13 Our results indicate that
cryptococcal polysaccharides,
especially GXM, can cause
14 the brain and, strikingly, in elimination of
cryptococcal polysaccharide from the brain.
15 Cryptococcal polysaccharides given intravenously to mice
16 Cryptococcal polysaccharides given intravenously to mice
17 Antibodies reactive with the
cryptococcal polysaccharide glucuronoxylomannan (GXM) ar
18 se of this investigation was to determine if
cryptococcal polysaccharides,
i.e., glucuronoxylomannan
19 coccosis typically have measurable levels of
cryptococcal polysaccharide in serum samples but minimal
20 Results showed that subjects with
cryptococcal polysaccharide in serum samples have signif
21 High titers of
cryptococcal polysaccharides in the serum and spinal flu
22 isseminated cryptococcosis is accompanied by
cryptococcal polysaccharides in the serum and the lack o
23 In vitro data have shown that
cryptococcal polysaccharide induces L-selectin (CD62L) s
24 The focus here was to determine whether
cryptococcal polysaccharides modulate the expression of